Online inquiry

IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7783MR)

This product GTTS-WQ7783MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MMP9 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_004994.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4318
UniProt ID P14780
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7783MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4577MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ5041MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ15104MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ7192MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ9664MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ50MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ4958MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ5801MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CFZ-533
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW